UNLABELLED: [F-18]Mefway was developed to provide an F-18 labeled positron emission tomography (PET) neuroligand with high affinity for the serotonin 5-HT(1A) receptor to improve the in vivo assessment of the 5-HT(1A) system. The goal of this work was to compare the in vivo kinetics of [F-18]mefway, [F-18]MPPF, and [C-11]WAY100635 in the rhesus monkey. METHODS: Each of four monkeys were given bolus injections of [F-18]mefway, [C-11]WAY100635, and [F-18]MPPF and scans were acquired with a microPET P4 scanner. Arterial blood was sampled to assay parent compound throughout the time course of the PET experiment. Time activity curves were extracted in the high 5-HT(1A) binding areas of the anterior cingulate cortex (ACG), mesial temporal cortex, raphe nuclei, and insula cortex. Time activity curves were also extracted in the cerebellum, which was used as a reference region. The in vivo kinetics of the radiotracers were compared based on the nondisplaceable distribution volume (V(ND) ) and binding potential (BP(ND) ). RESULTS: At 30 min, the fraction of radioactivity in the plasma due to parent compound was 19%, 28%, and 29% and cleared from the arterial plasma at rates of 0.0031, 0.0078, and 0.0069 (min⁻¹) ([F-18]mefway, [F-18]MPPF, [C-11]WAY100635). The BP(ND) in the brain regions were mesial temporal cortex: 7.4 ± 0.6, 3.1 ± 0.4, 7.0 ± 1.2, ACG: 7.2 ± 1.2, 2.1 ± 0.2, 7.9 ± 1.2; raphe nuclei: 3.7 ± 0.6, 1.3 ± 0.3, 3.3 ± 0.7; and insula cortex: 4.2 ± 0.6, 1.2 ± 0.1, 4.7 ± 1.0 for [F-18]mefway, [F-18]MPPF, and [C-11]WAY100635 respectively. CONCLUSIONS: In the rhesus monkey, [F-18]mefway has similar in vivo kinetics to [C-11]WAY100635 and yields greater than 2-fold higher BP(ND) than [F-18]MPPF. These properties make [F-18]mefway a promising radiotracer for 5-HT(1A) assay, providing higher counting statistics and a greater dynamic range in BP(ND).
UNLABELLED: [F-18]Mefway was developed to provide an F-18 labeled positron emission tomography (PET) neuroligand with high affinity for the serotonin 5-HT(1A) receptor to improve the in vivo assessment of the 5-HT(1A) system. The goal of this work was to compare the in vivo kinetics of [F-18]mefway, [F-18]MPPF, and [C-11]WAY100635 in the rhesus monkey. METHODS: Each of four monkeys were given bolus injections of [F-18]mefway, [C-11]WAY100635, and [F-18]MPPF and scans were acquired with a microPET P4 scanner. Arterial blood was sampled to assay parent compound throughout the time course of the PET experiment. Time activity curves were extracted in the high 5-HT(1A) binding areas of the anterior cingulate cortex (ACG), mesial temporal cortex, raphe nuclei, and insula cortex. Time activity curves were also extracted in the cerebellum, which was used as a reference region. The in vivo kinetics of the radiotracers were compared based on the nondisplaceable distribution volume (V(ND) ) and binding potential (BP(ND) ). RESULTS: At 30 min, the fraction of radioactivity in the plasma due to parent compound was 19%, 28%, and 29% and cleared from the arterial plasma at rates of 0.0031, 0.0078, and 0.0069 (min⁻¹) ([F-18]mefway, [F-18]MPPF, [C-11]WAY100635). The BP(ND) in the brain regions were mesial temporal cortex: 7.4 ± 0.6, 3.1 ± 0.4, 7.0 ± 1.2, ACG: 7.2 ± 1.2, 2.1 ± 0.2, 7.9 ± 1.2; raphe nuclei: 3.7 ± 0.6, 1.3 ± 0.3, 3.3 ± 0.7; and insula cortex: 4.2 ± 0.6, 1.2 ± 0.1, 4.7 ± 1.0 for [F-18]mefway, [F-18]MPPF, and [C-11]WAY100635 respectively. CONCLUSIONS: In the rhesus monkey, [F-18]mefway has similar in vivo kinetics to [C-11]WAY100635 and yields greater than 2-fold higher BP(ND) than [F-18]MPPF. These properties make [F-18]mefway a promising radiotracer for 5-HT(1A) assay, providing higher counting statistics and a greater dynamic range in BP(ND).
Authors: C Tai; A Chatziioannou; S Siegel; J Young; D Newport; R N Goble; R E Nutt; S R Cherry Journal: Phys Med Biol Date: 2001-07 Impact factor: 3.609
Authors: Richard E Carson; Yanjun Wu; Lixin Lang; Ying Ma; Margaret G Der; Peter Herscovitch; William C Eckelman Journal: J Cereb Blood Flow Metab Date: 2003-02 Impact factor: 6.200
Authors: R M Kessler; M S Ansari; T de Paulis; D E Schmidt; J A Clanton; H E Smith; R G Manning; D Gillespie; M H Ebert Journal: J Nucl Med Date: 1991-08 Impact factor: 10.057
Authors: Dustin W Wooten; Ansel T Hillmer; Jeffrey M Moirano; Elizabeth O Ahlers; Maxim Slesarev; Todd E Barnhart; Jogeshwar Mukherjee; Mary L Schneider; Bradley T Christian Journal: J Cereb Blood Flow Metab Date: 2012-04-04 Impact factor: 6.200
Authors: Ansel T Hillmer; Dustin W Wooten; Alisha K Bajwa; Andrew T Higgins; Patrick J Lao; Tobey J Betthauser; Todd E Barnhart; Howard A Rowley; Charles K Stone; Sterling C Johnson; Jogeshwar Mukherjee; Bradley T Christian Journal: J Nucl Med Date: 2014-11-13 Impact factor: 10.057
Authors: Dustin W Wooten; Ansel T Hillmer; Dhanabalan Murali; Todd E Barnhart; Joanne P Thio; Alisha K Bajwa; Ali A Bonab; Marc D Normandin; Mary L Schneider; Jogeshwar Mukherjee; Bradley T Christian Journal: Am J Nucl Med Mol Imaging Date: 2014-08-15
Authors: Joanne P Thio; Christopher Liang; Alisha K Bajwa; Dustin W Wooten; Bradley T Christian; Jogeshwar Mukherjee Journal: Med Chem Res Date: 2015-04 Impact factor: 1.965
Authors: Dustin W Wooten; Ansel T Hillmer; Jeffrey M Moirano; Dana L Tudorascu; Elizabeth O Ahlers; Maxim S Slesarev; Todd E Barnhart; Jogeshwar Mukherjee; Mary L Schneider; Bradley T Christian Journal: Neuroimage Date: 2013-03-26 Impact factor: 6.556
Authors: Bradley T Christian; Dustin W Wooten; Ansel T Hillmer; Dana L Tudorascu; Alexander K Converse; Colleen F Moore; Elizabeth O Ahlers; Todd E Barnhart; Ned H Kalin; Christina S Barr; Mary L Schneider Journal: J Neurosci Date: 2013-02-06 Impact factor: 6.167